Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: Results of the PRECISION v study

CardioVascular and Interventional Radiology

Volumn 33, Issue 1, 2010, Pages 41-52

  Lammer, Johannes ^a   Malagari, Katarina ^b   Vogl, Thomas ^c   Pilleul, Frank ^d   Denys, Alban ^e   Watkinson, Anthony ^f   Pitton, Michael ^g   Sergent, Geraldine ^h   Pfammatter, Thomas ⁱ   Terraz, Sylvain ^j   Benhamou, Yves ^k   Avajon, Yves ^l   Gruenberger, Thomas ^a   Pomoni, Maria ^b   Langenberger, Herbert ^a   Schuchmann, Marcus ^g   Dumortier, Jerome ^d   Mueller, Christian ^a   Chevallier, Patrick ^m   Lencioni, Riccardo ⁿ  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF ATHENS   (Greece)

^c GOETHE UNIVERSITY   (Germany)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^g JOHANNES GUTENBERG UNIVERSITY   (Germany)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^j GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^k PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^l HÔPITAL PAUL BROUSSE   (France)

^m CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

ⁿ CISANELLO HOSPITAL   (Italy)

more..

Author keywords

Chemoembolization; Doxorubicin; Drug eluting beads; Hepatocellular carcinoma

Indexed keywords

DOXORUBICIN;

ADULT; AGED; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CONTROL; CHEMOEMBOLIZATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INOPERABLE CANCER; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; SINGLE BLIND PROCEDURE; SKIN DISCOLORATION; TREATMENT RESPONSE;

EID: 77949264899     PISSN: 01741551     EISSN: 1432086X     Source Type: Journal    
DOI: 10.1007/s00270-009-9711-7     Document Type: Article

References (33)

1. SF Altekruse KA McGlynn ME Reichman 2009 Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005 J Clin Oncol 27 1485 1491 10.1200/JCO.2008.20.7753 19224838
2. M Höpfner D Schuppan H Scherübl 2008 Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer World J Gastroenterol 14 1 14 10.3748/wjg.14.1 18176955 (Pubitemid 351314320)
3. JM Llovet C Bru J Bruix 1999 Prognosis of hepatocellular carcinoma: The BCLC staging classification Semin Liver Dis 19 329 338 10.1055/s-2007-1007122 1:STN:280:DyaK1Mvks1Grsg%3D%3D 10518312
4. J Bruix JM Llovet 2002 Prognostic prediction and treatment strategy in hepatocellular carcinoma Hepatology 35 519 524 10.1053/jhep.2002.32089 11870363 (Pubitemid 34183954)
5. BH O'Neil AP Venook 2007 Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy Oncologist 12 1425 1432 10.1634/theoncologist.12-12-1425 18165619
6. J Bruix M Sherman 2005 Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma Hepatology 42 1208 1236 10.1002/hep.20933 16250051 (Pubitemid 43112690)
7. RG Gish C Porta L Lazar, et al. 2007 Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin J Clin Oncol 25 3069 3075 10.1200/JCO.2006.08.4046 1:CAS:528:DC%2BD2sXptlGrsbc%3D 17634485 (Pubitemid 47218053)
8. JM Llovet S Ricci V Mazzaferro, et al. 2008 Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378 390 10.1056/NEJMoa0708857 1:CAS:528:DC%2BD1cXovFWjsL8%3D 18650514
9. JL Raoul D Heresbach JF Bretagne, et al. 1992 Chemoembolisation of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin Cancer 70 585 590 10.1002/1097-0142(19920801)70:3<585::AID- CNCR2820700308>3.0.CO;2-# 1:STN:280:DyaK38zitlCrsw%3D%3D 1320447
10. DY Lin YF Liaw TY Lee CM Lai 1988 Hepatic arterial embolisation in patients with unresectable hepatocellular carcinoma-a randomised controlled trial Gastroenterology 94 453 456 1:STN:280:DyaL1c%2FosVarsA%3D%3D 2826285
11. Group d'Etude et de Traitment du Carcinome Hépatocellulaire 1995 A comparison of lipiodol chemoembolisation and conservative treatment for unresectable hepatocellular carcinoma N Engl J Med 332 1256 1261 10.1056/NEJM199505113321903
12. 131I-labeled- iodized oil in the treatment of hepatocellular carcinoma Hepatology 26 1156 1161 1:CAS:528:DyaK2sXntl2jtrY%3D 9362356
13. J Bruix JM Llovet A Castells, et al. 1998 Transarterial embolisation versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomised, controlled trial in a single institution Hepatology 27 1578 1583 10.1002/hep.510270617 1:STN:280:DyaK1c3otFKnsg%3D%3D 9620330 (Pubitemid 28264682)
14. G Pelletier M Ducreux F Gay, et al. 1998 Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolisation: a multicentre randomised trial J Hepatol 29 129 134 10.1016/S0168-8278(98)80187-6 1:CAS:528:DyaK1cXmvVWhsLk%3D 9696501 (Pubitemid 28307992)
15. CM Lo H Ngan WK Tso, et al. 2002 Randomised controlled trial of transarterial lipiodol chemoembolisation for unresectable hepatocellular carcinoma Hepatology 35 1164 1171 10.1053/jhep.2002.33156 1:CAS:528: DC%2BD38XktF2hu7w%3D 11981766 (Pubitemid 34454013)
16. JM Llovet MI Real X Montana, et al. 2002 Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial Lancet 359 1734 1739 10.1016/S0140-6736(02)08649-X 12049862 (Pubitemid 34607087)
17. JM Llovet J Bruix for the Barcelona-Clínic Liver Cancer Group 2003 Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolisation improves survival Hepatology 37 429 442 10.1053/jhep.2003.50047 1:CAS:528:DC%2BD3sXhsFeltrg%3D 12540794 (Pubitemid 36152543)
18. L Marelli R Stigliano C Triantos, et al. 2007 Transarterial therapy for hepatocellular carcinoma: Which technique is more effective? A systematic review of cohort and randomized studies Cardiovasc Interv Radiol 30 6 25 10.1007/s00270-006-0062-3 (Pubitemid 44900485)
19. AL Lewis MV Gonzales AW Lloyd, et al. 2006 DC Bead: in vitro characterisation of a drug-delivery device for transarterial chemoembolisation J Vasc Interv Radiol 17 335 342 16517780
20. AL Lewis MV Gonzalez SW Leppard, et al. 2007 Doxorubicin eluting beads. 1. Effects of drug loading on bead characteristics and drug distribution J Mater Sci Mater Med 18 1691 1699 10.1007/s10856-007-3068-8 1:CAS:528: DC%2BD2sXos1Cgu7o%3D 17483878 (Pubitemid 47224923)
21. AL Lewis RR Taylor B Hall, et al. 2006 Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolisation J Vasc Interv Radiol 17 1335 1343 16923981
22. K Hong A Khwaja E Liapi, et al. 2006 New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer Clin Cancer Res 12 2563 2567 10.1158/1078-0432.CCR-05-2225 1:CAS:528:DC%2BD28XjvValu7k%3D 16638866
23. M Varela MI Real M Burrel, et al. 2007 Chemoembolisation of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics J Hepatol 46 474 481 10.1016/j.jhep.2006.10.020 1:CAS:528:DC%2BD2sXhtlCmtb0%3D 17239480 (Pubitemid 46201723)
24. RT Poon WK Tso RW Pang, et al. 2007 A phase I/II trial of chemoembolisation for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead Clin Gastroenterol Hepatol 5 1100 1108 10.1016/j.cgh.2007.04. 021 1:CAS:528:DC%2BD2sXhtFKrt7%2FE 17627902
25. J Kettenbach A Stadler IV Katzler, et al. 2008 Drug-loaded microspheres for the treatment of liver cancer: review of current results Cardiovasc Interv Radiol 31 468 476 10.1007/s00270-007-9280-6
26. K Malagari K Chatzimichael E Alexopöulou, et al. 2008 Transarterial chemoembolisation of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients Cardiovasc Interv Radiol 31 269 280 10.1007/s00270-007-9226-z
27. JM Llovet AM Di Bisceglie J Bruix Panel of Experts in HCC-Design Clinical Trials, et al. 2008 Design and endpoints of clinical trials in hepatocellular carcinoma J Natl Cancer Inst 100 698 711 10.1093/jnci/djn134 18477802
28. D Moher KF Schulz DG Altman 2001 The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials Lancet 357 1191 1194 10.1016/S0140-6736(00)04337-3 1:STN:280:DC%2BD3MzisFehtQ%3D%3D 11323066 (Pubitemid 32378696)
29. S Hopewell M Clarke D Moher, et al. 2008 CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts Lancet 371 281 283 10.1016/S0140-6736(07)61835-2 18221781
30. J Bruix M Sherman JM Llovet, et al. 2001 Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver J Hepatol 35 421 430 10.1016/S0168-8278(01)00130-1 1:STN:280:DC%2BD3MrksFCmtg%3D%3D 11592607 (Pubitemid 32844200)
31. SK Wang AA Tsiatis 1987 Approximately optional one-parameter boundaries for group sequential trials Biometrics 43 193 199 10.2307/2531959 1:STN:280:DyaL2s7osFOiuw%3D%3D 3567304 (Pubitemid 17063902)
32. M Satake H Uchida Y Arai, et al. 2008 Transcatheter arterial chemoembolization (TACE) with lipiodol to treat hepatocellular carcinoma: survey results from the TACE study group of Japan Cardiovasc Interv Radiol 31 756 761 10.1007/s00270-007-9255-7
33. M Grosso C Vignali P Quaretti, et al. 2008 Transarterial chemoembolization of hepatocellular carcinoma with drug-eluting microspheres: preliminary results from an Italian multicenter study Cardiovasc Interv Radiol 31 1141 1149 10.1007/s00270-008-9409-2